Tiziana life sciences plc (“tiziana” or “the company”) - notification of proposed admission to the main market and cancellation of trading on aim

London and new york, dec. 17, 2020 (globe newswire) -- tiziana life sciences plc (nasdaq: tlsa / aim: tils) ("tiziana" or the "company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces it has applied to list its ordinary shares ("ordinary shares") on the standard listing segment of the official list of the financial conduct authority (“fca”) (the "official list") and admission to trading on the london stock exchange plc's (the "london stock exchange") main market ("main market") for listed securities (together, "admission"). the board has taken this decision as it believes that a standard listing will afford tiziana greater flexibility in pursuing its strategy as an international company.
TLSA Ratings Summary
TLSA Quant Ranking